Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
5 Puneet Maheshwari (Investor Relations), Alisha Moopen (MD & Group CEO), Dr. Azad Moopen (Executive Chairman), Sunil Chandra Mishra (Group CFO), Varun Khanna (MD & Group CEO Designate)
Analysts
8 Bino, Damayanti Kerai (HSBC Global Investment Research), Harit, Mohammed, Nitin Shakdher (Green Capital Single Family Office), Saket, Siddharth, Tausif Shaikh (BNP Paribas)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations (Combined Pro Forma) | ₹2,597 crores | +20% YoY; driven by higher patient volumes, supported by realization gains from complex case mix |
| EBITDA (Combined Pro Forma) | ₹576 crores | +30% YoY; operating leverage through cost savings and fixed cost absorption |
| EBITDA Margin (Combined) | 22.2% | +170 bps YoY; mature unit margin at 30% (+230 bps) anchored overall expansion |
| Patient Throughput (Combined) | 2.0 million+ | +13% YoY; ~8 million patients served over trailing 12 months |
| Blended Occupancy (Combined) | 64.0% | +510 bps YoY; Quality Care occupancy at 65.4% (+656 bps) |
| Medical Value Travel (MVT) Growth | +62% YoY | Aided by new geographies and structured sales teams; contribution base still low vs peers |
| Aster DM Standalone Revenue | ₹1,311 crores | +22% YoY (vs ₹1,078 cr); volume-led with IP throughput +16%, ARPP IP +10% |
| Aster DM Standalone Operating EBITDA | ₹277 crores | +29% YoY; margin 21.1% (+117 bps) |
| Aster DM Normalized PAT | ₹125 crores | +39% YoY (vs ₹90 cr); excludes ₹114 cr one-time merger costs |
| Quality Care Revenue | ₹1,287 crores | +19% YoY; boosted by deeper clinical mix and better payor mix |
| Quality Care Operating EBITDA | ₹299 crores | +32% YoY; margin 23.2% (+216 bps); ARPP IP ₹144K |
| ROCE (Aster DM) | 22.6% | +190 bps YoY; reflects higher operating earnings and better asset utilization |
| Net Debt (Combined) | ₹1,162 crores | Aster net cash ₹511 cr; Quality Care debt ₹1,673 cr as of June 30, 2026 |
| Segment: Mature Units (73% of revenue) | Revenue +19% YoY; EBITDA +29%; margin 30% | +230 bps margin YoY; steady bed throughput, better case mix and NBT contribution |
| Segment: Focus Units (15% of revenue) | Revenue +16% YoY; EBITDA +20%; margin expansion +60 bps | Expanding specialty programs and rising occupancy driving rapid margin gains |
| Segment: Emerging Units (12% of revenue) | Revenue +63% YoY; EBITDA +240%; margin 12.4% | +640 bps YoY; Kasaragod achieved EBITDA breakeven in June 2026, 9 months post-commissioning |
Geographic & Segment Commentary
- Kerala: Revenue growth of 25% YoY (20% ex-Kasaragod), fully volume-led with 16%+ IP and 19% OP volume growth; Aster Medcity crossed ₹100 crores revenue in Q1 alone. Recovery driven by post-leadership-change system building rather than individual dependence.
- Karnataka / Bengaluru: Growth rebounded from single digits to 16% YoY with 5-6% volume growth; 18+ doctors added in Bengaluru (Q1 FY27). All three Bangalore hospitals (CMI, Whitefield, RV) clocked record monthly revenue in June 2026 following earlier clinical attrition recovery.
- Tier 2/Tier 3 Cities: Emerging segment grew 63% YoY with margins at 12.4%; Nagercoil turned profitable in 4 months with ~₹180 crores run-rate revenue and ~30% EBITDA; Kasaragod breakeven in 9 months; Raipur cancer center inauguration slated mid-August 2026.
- Clinical Complexity Portfolio: Orthopedics, neurology, oncology each grew 24%+; robotic volumes +80%, joint replacements +39%, transplants +19% YoY; MVT grew 62% on low base with structured capability build-out.
Company-Specific & Strategic Commentary
- Merger Completion & Integration: Merger of Aster DM and Quality Care effective July 1, 2026; combined entity spans 39 hospitals, ~10,800 beds, 7,400 clinicians, 28 cities, 9 states. Enterprise-wide "Go Greater" cultural integration conducted with zero operational friction or service disruption.
- Synergy Realization Plan: 10-point synergy wheel targeting 10-15% incremental EBITDA on FY24 pro forma base (₹150-₹200 crores); synergies (procurement, clinical program sharing, digital) have not yet played out—combined Q1 performance is purely from independent entity execution.
- Expansion Roadmap: 4,170 beds planned over 3-4 years to reach 15,000 beds; 53% brownfield for faster gestation and higher ROCE. Key projects: Trivandrum (Jan 2027), Hyderabad (~April 2027), Sarjapur phase 1 (H2 FY28), plus Bhubaneswar, Kottayam, Nagercoil and Banjara Hills additions; 159-bed Women & Children block commissioned at Aster Whitefield April 2026.
- Clinical Capability Building: CARE Hitech secured JCI accreditation (first CARE unit); India's first robotic HAI therapy for non-curable liver metastasis and Kerala's first transcatheter Fontan performed; programs like DBS (top-5 in Asia, Kochi) and liver transplant to be extended across the network.
- Organizational Structure: Matrix setup with three India CEOs (clusters: parts of Kerala/Maharashtra, another part of Kerala/Karnataka, and AP-Telangana-Central-East) overlaying clinical specialty verticals (oncology, cardiology) and maturity-based management cuts; reporting to shift to maturity/geography mix.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin (Combined) | 24%-25% in 2-3 years (between FY28-FY29) | Management reaffirmed; strong exit expected in FY27 (~22%+ current); driven by maturity progression, synergy realization and operating leverage |
| Synergy EBITDA | 10%-15% incremental on FY24 pro forma EBITDA (₹150-₹200 crores) | Commitment intact; to be realized from procurement, clinical program sharing, and cost synergies starting FY27 onwards |
| MVT Growth / Contribution | Growth >50% annually; contribution to mid-single then double-digit in 2-3 years | Base low vs peers; investments in sales structure, CRM, digital lead tracking and global outcomes driving catch-up growth |
| Organic Growth Drivers | 5%-6% volume + 7%-8% ARPP growth | Sustainability framework stated by CFO to support margin and revenue trajectory |
| Bed Expansion | 4,170 beds over 3-4 years to 15,000 beds; 53% brownfield | Trivandrum (H2 FY27 |
Risks & Constraints
| Risk | Context |
|---|---|
| Merger Integration Execution | Synergies and cultural integration carry execution risk; management claims zero operational friction during day-1 alignment, but synergy realization is a multi-quarter process with inherent complexity in a matrix org structure |
| Competitive Intensity | Bengaluru and select micro-markets seeing new competitive capacity; management noted historical softness of 1-2 quarters when neighborhood competition enters, mitigated by clinical reputation, doctor attraction and digital enablement |
| Clinical Talent Attrition | Recent attrition episodes in Bengaluru (FY26) impacted growth to single digits; management highlighted doctor re-hiring (18+ in Bengaluru) and system-based operations as mitigation; 39-hospital network amplifies exposure to key-person dependence |
| New Hospital Ramp-Up / Execution | Heavy expansion pipeline (4,170 beds) across greenfield/brownfield carries commissioning and occupancy ramp-up risk; however, recent track record (Kasaragod 9-month breakeven, Nagercoil 4-month profitability) provides confidence |
| MVT Dependence on Geopolitics/Referral Channels | 62% growth on low base; growth assumes continued international patient flows and referral infrastructure; management building dedicated teams and CRM to sustain >50% growth |
Q&A Highlights
Organizational Structure & Strategy Priorities
- Question: How is the merged entity structured—clusters, brand approach, and near-term priorities? (Tausif Shaikh)
- Answer: Structuring based on geographical contiguity, business continuity, and span of control; four maturity cuts overlaid. Top priorities: (1) post-merger integration and synergy unlocking, (2) operational and clinical standards/sustainability oversight, (3) long-term strategic roadmap. No clinical "gaps" perceived—continuous investment in talent and technology is the norm. (Varun Khanna)
EBITDA Margin Trajectory & Synergy Timing
- Question: When will 24-25% EBITDA margin be reached given the strong Q1 start? (Tausif Shaikh, Mohammed)
- Answer: No quarterly/annual guidance offered; broader 2-3 year target of 24-25% maintained with strong FY27 exit expected. Synergies of 10-15% on FY24 pro forma EBITDA (₹150-₹200 crores) are committed; this is a near-term target with potential upside. (Varun Khanna, Sunil Chandra Mishra)
Synergy Value & Clinical Talent Leverage
- Question: What are the low-hanging cost synergies and clinical talent opportunities and beyond existing program-level sharing? (Damayanti Kerai)
- Answer: Combined Q1 performance was purely independent-entity driven—synergies begin now. 10-point synergy wheel includes indirect procurement (large scale leverage) and clinical program sharing; magnitude guided at 10-15% incremental EBITDA. Clinical synergies enable extension of complex programs (e.g., DBS from Kochi, liver transplant teams) across 39 hospitals, unlocking scale in high-acuity care. (Varun Khanna)
Medical Value Travel Growth & Strategy
- Question: What is driving 62% MVT growth vs peers? (Damayanti Kerai, Saket)
- Answer: Low base; structured sales teams, CRM/lead tracking, digital interventions, and better clinical outcomes driving referrals; 8 million annual patients generate word-of-mouth. Target is mid-single to double-digit contribution over 2-3 years with growth >50% sustained. (Varun Khanna, Alisha Moopen)
Kerala/Maharashtra/Karnataka Performance
- Question: What explains strong Kerala and comparatively slower Maharashtra/Karnataka growth? (Siddharth)
- Answer: Kerala recovered from -5% degrowth in Q4 FY25 (leadership change) to 25% growth in Q1 FY27 (20% ex-Kasaragod), volume-led. Karnataka moved from single-digit to 16% with record June revenues at all three Bangalore hospitals (CMI, Whitefield, RV) after adding 18 doctors; Maharashtra not explicitly addressed but softness attributed to scheme rationalization earlier. (Sunil Chandra Mishra)
Maturity Cut Reporting & Future Disclosure
- Question: Will reporting be maturity-based or geography-based going forward? (Siddharth, Mohammed)
- Answer: Maturity cuts are critical—73% of revenue from mature units (EBITDA >25% at unit level). Reporting will add maturity segments alongside some geographical data; QCIL/Aster branding distinction ended (one company, 39 assets, 10,800 beds). Geographic breakup to be refined over next quarter. (Varun Khanna)
Competition in Bengaluru & Sustainability
- Question: Is the 20-30% Bangalore growth sustainable with rising competition? (Bino)
- Answer: Historical pattern: 1-2 quarters of softness when neighborhood competition enters, then recovery. Sustainability supported by double-digit volume growth (5-6% volume, 7-8% ARPP), strong clinical practice, doctor credibility (re-joining teams), and brand strength; merged entity enhances capability and clinician attraction. (Sunil Chandra Mishra, Varun Khanna)
Greenfield Expansion Timelines & Brand Convergence
- Question: Timelines for Trivandrum, Hyderabad, Sarjapur and brand strategy? (Harit)
- Answer: Trivandrum operational ~January 2027 (H2 FY27); Hyderabad ~April 2027 (start of FY28) post-interior/equipment; Sarjapur phase 1 in H2 FY28. Brand convergence premature—mergers differ from acquisitions; micro-market brand strengths will guide future decisions. (Sunil Chandra Mishra)
Payer/Health System Strategy
- Question: Any plans to evolve into an integrated health system with payer capabilities? (Saket)
- Answer: Focus remains on core hospital operations; robust insurer partnerships exist to serve patients; no near/mid-term payer integration plans—"enough on the platter" in current model. (Varun Khanna)
FY28 Expansion Details (QCIL)
- Question: Hospital-wise QCIL expansion for FY27/FY28? (Mohammed)
- Answer: Raipur cancer center opens mid-August 2026; Bhubaneswar is a big upcoming project; Kottayam capacity addition in 2028; Nagercoil and Banjara Hills bed additions; small adds at Nampally and Shifa. Total quantum guided via year-by-year brownfield/greenfield split—₹/bed details to be shared offline. (Sunil Chandra Mishra)
Key Takeaway
Aster DM Quality Care delivered a strong combined pro forma Q1 FY27—revenue up 20% YoY to ₹2,597 crores, EBITDA up 30% to ₹576 crores with margin expanding 170 bps to 22.2%—marking the first reported quarter as a unified entity post the July 1 merger. Both legacy platforms contributed independently: Aster DM grew revenue 22% (EBITDA margin 21.1%, ROCE 22.6%) and Quality Care grew 19% (margin 23.2%), with emerging hospitals (+63%) and MVT (+62%) leading growth. Management emphasized that merger synergies (10-15% incremental EBITDA on FY24 pro forma base, ₹150-₹200 crores) have yet to play out, with a 10-point synergy wheel now activating across procurement and clinical program sharing. Strategic focus is on scaling super-specialty care, expanding into tier 2/3 geographies via 4,170 new beds (53% brownfield) targeting 15,000 beds, and driving patient-centric digital innovation; oncology and complex programs (robotics +80%, transplants +19%) are priority. Management reaffirmed the 24-25% EBITDA margin target within 2-3 years and a disciplined growth framework, while watch-points include Bengaluru competition, clinical talent retention, and greenfield commissioning timelines. The integrated platform—39 hospitals, 7,400 clinicians, 8 million patients annually—positions it to deepen access across 28 cities and 9 states, with MVT contribution targeted to reach double digits in the medium term.
Transcript incomplete - Some Q&A participant affiliations are not fully identified; financial statements for combined entity on pro forma basis noted.